Novel nanometrically structured therapeutic hydrogel as injectable for fascial tissues surrounding the nerves intended for preventive treatment of chronic pain

Projektinformationen

TherGelFas

ID Finanzhilfevereinbarung: 795417

DOI 10.3030/795417

Abgeschlossenes Projekt

EK-Unterschriftsdatum 11 Juli 2018

Startdatum 1 November 2018

Enddatum 31 Oktober 2020

Finanziert unter

• EXCELLENT SCIENCE - Marie Skłodowska-Curie Actions

Gesamtkosten € 170 121,60

EU-Beitrag € 170 121,60

Koordiniert durch

I+MED S COOP
Spain

Ziel

The key goals of the “TherGeLFas” project are: (a) the training of a talented experienced researcher in the fast growing field of innovative biomaterials for medical applications where the host and partner institutions have a critical knowledge and expertise; and, (b) the design and development of cost- efficient polymer materials in order to develop a new medicinal product for post-operative acute pain treatment and prevention of chronification.
The aim of the research project and the main scientific challenge is thereby to develop a ‘therapeutically effective’ hydrogel based injectable product to be applied during and post-surgery in the fascial tissue that protects the nerves where the pain originates and chronifies. TherGelFas expects to create the proof of concept of a new medicinal product by combining advanced materials (a biodegradable, antiseptic and biocompatible carrier, made of porous nanostructured hydrogel based on hyaluronic acid) with the ability to load and release non-steroidal antiinflamatory drugs in a controlled manner. It is aimed for the improvement of the current multimodal strategies of peripheral nerve blockade injections used during and post-surgery in acute pain treatment to prevent it from becoming chronic and that unfortunately are unsuccessful many times.
The first achievement will be that of the training of the experienced researcher in new areas of knowledge such as business development from original concept stages to production scale-up, manufacturing and marketing stages. The second achievement will be to scientifically assess whether these hydrogels can improve and replace currently used therapies, to develop a proof-of-concept scalable product. The third achievement will be to learn how to perform correctly the necessary steps needed to launch a product of this kind, such as record and prepare all the documentation needed to present the product to the corresponding regulatory agencies.

Wissenschaftliches Gebiet

• medical and health sciences › basic medicine › pharmacology and pharmacy › pharmaceutical drugs
• natural sciences › chemical sciences › polymer sciences
• engineering and technology › industrial biotechnology › biomaterials

Programm/Programme

• H2020-EU.1.3. - EXCELLENT SCIENCE - Marie Skłodowska-Curie Actions Main Programme
• H2020-EU.1.3.2. - Nurturing excellence by means of cross-border and cross-sector mobility

Thema/Themen

• MSCA-IF-2017 - Individual Fellowships

Aufforderung zur Vorschlagseinreichung

H2020-MSCA-IF-2017

Finanzierungsplan

MSCA-IF-EF-SE - Society and Enterprise panel

Koordinator

I+MED S COOP

• Netto-EU-Beitrag: € 170 121,60
• Adresse: CALLE ALBERT EINSTEIN 15 ; 01510 Vitoria-Gasteiz ; Spanien
• KMU Die Organisation definierte sich zum Zeitpunkt der Unterzeichnung der Finanzhilfevereinbarung selbst als KMU (Kleine und mittlere Unternehmen). Ja:
  Region
  Noreste › País Vasco › Araba/Álava
• Region: Noreste › País Vasco › Araba/Álava
• Aktivitätstyp: Private for-profit entities (excluding Higher or Secondary Education Establishments)
• Gesamtkosten: € 170 121,60